按需使用毛果芸香碱治疗头颈癌放疗后口干症
本研究为随机双盲安慰剂对照交叉试验,纳入20例头颈癌放疗后口干症患者,按需使用毛果芸香碱或安慰剂各2周,中间洗脱1周。毛果芸香碱治疗期口干量表(XI)评分较安慰剂期显著降低,平均差异-18.05(95%CI:-17.17,-6.13,p<0.001),变化为-49.77±3.22%(p<0.001);仅1例因毛果芸香碱副作用退出。
要点
- 按需使用毛果芸香碱可显著降低头颈癌放疗后口干症患者的XI评分。
- 毛果芸香碱治疗期XI评分较安慰剂期平均差异-18.05(95%CI:-17.17,-6.13,p<0.001)。
- 仅1例因毛果芸香碱副作用退出,按需方案副作用较少且治疗成本较低。
核心结论
- 按需使用毛果芸香碱可有效缓解头颈癌放疗后口干症症状,且较固定剂量方案副作用更少、治疗成本更低。
研究设计与样本
- 随机双盲安慰剂对照交叉研究,纳入因头颈癌接受放疗后出现口干症的患者,共20例完成交叉研究。
- 参与者按需服用毛果芸香碱或安慰剂以缓解症状,每种治疗为期2周,期间包括1周洗脱期。
- 主要结局指标为采用口干量表(XI)量化的口干症状严重程度,主要结局为XI评分变化。
主要发现
- 在完成交叉研究的20例参与者中,毛果芸香碱治疗期XI评分较安慰剂期显著降低。
- XI评分平均差异为-18.05(95%CI:-17.17,-6.13,p<0.001),变化为-49.77±3.22%(p<0.001)。
- 仅1例参与者因毛果芸香碱副作用退出。
临床怎么用
- 作者认为按需使用毛果芸香碱是缓解头颈癌放疗后口干症的有效方式,较固定剂量方案副作用更少且治疗成本更低。
- 作者认为本研究为临床实践中转向灵活给药策略提供了指导,有助于促进以患者为中心的个体化护理和依从性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aimed to evaluate the efficacy of as-needed pilocarpine for the management of radiation-induced xerostomia. Additionally, the study sought to assess the side effects associated with an as-needed regimen. METHODS: A randomized, double-blinded, placebo-controlled crossover study was conducted on patients who had undergone radiation therapy for head and neck cancers and developed xerostomia. Participants took pilocarpine or placebo as needed for symptom relief at 2 weeks per treatment, which included a one-week washout period. The primary outcome measure was the severity of dry mouth symptoms, quantified using the Xerostomia Inventory (XI). The primary outcome was the change in the XI score. RESULTS: Among the 20 participants who completed the crossover study, there was a significant reduction in XI scores during the treatment phase with pilocarpine compared to the scores during the placebo phase. The mean difference in XI scores was -18.05 (95% CI: -17.17, -6.13, p < 0.001), with a-49.77 ± 3.22% change (p < 0.001). Only one participant withdrew due to pilocarpine side effects. CONCLUSION: As-needed pilocarpine administration is effective in relieving symptoms of radiation-induced xerostomia, with fewer side effects and reduced treatment costs compared to fixed-dose regimens. This study guides the potential shift toward flexible dosing strategies in clinical practice, promoting enhanced patient-centered, tailored care and adherence. LEVEL OF EVIDENCE: 2: According to the Oxford Center for Evidence-Based Medicine 2011 level of evidence guidelines Laryngoscope, 134:4542-4548, 2024.
引用
- Watanapokasin N, Rawangban W, Tangjaturonrasme N, et al. As-Needed Pilocarpine for Radiation-Induced Xerostomia in Head and Neck Cancers. Laryngoscope. 2024. PMID: 38813852. doi:10.1002/lary.31544
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。